Giuseppe
Emeritus
[Source: PLoS ONE, full text: (LINK). Abstract, edited.]
Antiviral Therapy and Outcomes of Patients with Pneumonia Caused by Influenza A Pandemic (H1N1) Virus
by Shi-gui Yang, Bin Cao, Li-rong Liang, Xiao-li Li, Yong-hong Xiao, Zhi-xin Cao, Hong-yu Jia, Hong-jie Yu, Zhen Xu, Li Gu, Yi-da Yang, Yu Chen, Wei-bo Du, Xi-xin Yan, Zong-an Liang, Wei Zhang, Chang-le Zhang, Wei Chen, Cai-ping Guo, Xun-liang Jiang, Ming Yang, Guang-ming Deng, Kai-jiang Yu, Ke Hu, Qi Zou, Lan-juan Li, Chen Wang, for the National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China
Background
There is limited data on the clinical outcome of patients with pandemic H1N1 (pH1N1) pneumonia who received oseltamivir treatment, especially when the treatment was administered more than 48 hours after symptom onset.
Methods
During the pandemic in 2009, a cohort of pH1N1 influenza pneumonia was built in China, and their clinical information was collected systematically, and analyzed with Cox models.
Results
920 adults and 541 children with pneumonia who didn't receive corticosteroids were analyzed. In-hospital mortality was higher in adults who did not receive antiviral therapy (18.2%) than those with who received oseltamivir ≤ 2days (2.9%), between 2?5 days (4.6%) and >5 days after illness onset (4.9%), p5 days, respectively. For males patients, aged ≥ 14 years and baseline PaO<SUB>2</SUB>/FiO<SUB>2</SUB>3.8 mg/kg/d) did not improve clinical outcome (mortality, higher dose 2.5% vs standard dose 2.8%, p>0.05).
Conclusions
Antiviral therapy might reduce mortality of patients with pH1N1 pneumonia, even when initiated more than 48 hours after onset of illness. Greater protective effects might be in males, patients aged 14?60 years, and patients with PaO<SUB>2</SUB>/FiO<SUB>2</SUB><200.
- -------by Shi-gui Yang, Bin Cao, Li-rong Liang, Xiao-li Li, Yong-hong Xiao, Zhi-xin Cao, Hong-yu Jia, Hong-jie Yu, Zhen Xu, Li Gu, Yi-da Yang, Yu Chen, Wei-bo Du, Xi-xin Yan, Zong-an Liang, Wei Zhang, Chang-le Zhang, Wei Chen, Cai-ping Guo, Xun-liang Jiang, Ming Yang, Guang-ming Deng, Kai-jiang Yu, Ke Hu, Qi Zou, Lan-juan Li, Chen Wang, for the National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China
Background
There is limited data on the clinical outcome of patients with pandemic H1N1 (pH1N1) pneumonia who received oseltamivir treatment, especially when the treatment was administered more than 48 hours after symptom onset.
Methods
During the pandemic in 2009, a cohort of pH1N1 influenza pneumonia was built in China, and their clinical information was collected systematically, and analyzed with Cox models.
Results
920 adults and 541 children with pneumonia who didn't receive corticosteroids were analyzed. In-hospital mortality was higher in adults who did not receive antiviral therapy (18.2%) than those with who received oseltamivir ≤ 2days (2.9%), between 2?5 days (4.6%) and >5 days after illness onset (4.9%), p5 days, respectively. For males patients, aged ≥ 14 years and baseline PaO<SUB>2</SUB>/FiO<SUB>2</SUB>3.8 mg/kg/d) did not improve clinical outcome (mortality, higher dose 2.5% vs standard dose 2.8%, p>0.05).
Conclusions
Antiviral therapy might reduce mortality of patients with pH1N1 pneumonia, even when initiated more than 48 hours after onset of illness. Greater protective effects might be in males, patients aged 14?60 years, and patients with PaO<SUB>2</SUB>/FiO<SUB>2</SUB><200.